Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
Altimmune (ALT) announced key developments in Q3 2024, including completion of enrollment in the Phase 2b IMPACT trial of pemvidutide for MASH, with top-line data expected in Q2 2025. The company successfully completed its End-of-Phase 2 FDA meeting for pemvidutide's obesity program, planning four Phase 3 trials. At EASD, they presented promising data showing pemvidutide's lean mass preservation and visceral fat reduction. The company plans to submit INDs for up to three additional pemvidutide indications starting Q4 2024.
Financial results showed $139.4 million in cash and investments, R&D expenses of $19.8 million, and a net loss of $22.8 million ($0.32 per share) for Q3 2024.
Altimmune (ALT) ha annunciato sviluppi chiave nel terzo trimestre del 2024, compresa la conclusione dell'arruolamento nella fase 2b dello studio IMPACT per il pemvidutide nel trattamento della MASH, con dati preliminari attesi nel secondo trimestre del 2025. L’azienda ha completato con successo l'incontro FDA di fine fase 2 per il programma di obesità del pemvidutide, pianificando quattro studi di fase 3. Durante l'EASD, sono stati presentati dati promettenti che mostrano la preservazione della massa magra e la riduzione del grasso viscerale forniti dal pemvidutide. L'azienda prevede di presentare richieste IND per fino a tre ulteriori indicazioni del pemvidutide a partire dal quarto trimestre del 2024.
I risultati finanziari hanno mostrato 139,4 milioni di dollari in liquidità e investimenti, spese per R&S di 19,8 milioni di dollari e una perdita netta di 22,8 milioni di dollari (0,32 dollari per azione) per il terzo trimestre del 2024.
Altimmune (ALT) anunció desarrollos clave en el tercer trimestre de 2024, incluyendo la finalización de la inscripción en el ensayo de fase 2b IMPACT de pemvidutide para MASH, con datos preliminares esperados en el segundo trimestre de 2025. La compañía completó con éxito su reunión de fin de fase 2 con la FDA para el programa de obesidad del pemvidutide, planeando cuatro ensayos de fase 3. En el EASD, presentaron datos prometedores que muestran la preservación de la masa magra y la reducción de grasa visceral por parte del pemvidutide. La empresa tiene planes de presentar solicitudes IND para hasta tres indicaciones adicionales de pemvidutide a partir del cuarto trimestre de 2024.
Los resultados financieros mostraron 139,4 millones de dólares en efectivo e inversiones, gastos de I+D de 19,8 millones de dólares, y una pérdida neta de 22,8 millones de dólares (0,32 dólares por acción) para el tercer trimestre de 2024.
Altimmune (ALT)는 2024년 3분기 주요 개발 사항을 발표하였으며, 여기에는 MASH에 대한 pemvidutide의 2b 단계 IMPACT 시험에서 등록 완료가 포함되어 있으며, 주요 데이터는 2025년 2분기에 예상됩니다. 이 회사는 pemvidutide 비만 프로그램을 위한 2상 종료 미국 FDA 회의를 성공적으로 마쳤으며, 3개의 3상 시험을 계획하고 있습니다. EASD에서 그들은 pemvidutide의 근육량 보존 및 내장 지방 감소를 보여주는 유망한 데이터를 발표했습니다. 이 회사는 2024년 4분기부터 최대 3개의 추가 pemvidutide 적응증에 대한 IND를 제출할 계획입니다.
재무 결과는 3분기 2024년에 1억 3천940만 달러의 현금 및 투자, 1천980만 달러의 연구개발 비용, 2천280만 달러의 순손실(주당 0.32 달러)을 보여주었습니다.
Altimmune (ALT) a annoncé des développements clés au troisième trimestre 2024, y compris l'achèvement du recrutement dans l'essai de phase 2b IMPACT du pemvidutide pour la MASH, avec des données préliminaires attendues au deuxième trimestre 2025. L'entreprise a réussi à terminer sa réunion de fin de phase 2 avec la FDA pour le programme d'obésité du pemvidutide, prévoyant quatre essais de phase 3. Lors de l'EASD, ils ont présenté des données prometteuses montrant la préservation de la masse maigre et la réduction de la graisse viscérale grâce au pemvidutide. L'entreprise prévoit de soumettre des demandes IND pour jusqu'à trois indications supplémentaires de pemvidutide à partir du quatrième trimestre 2024.
Les résultats financiers ont montré 139,4 millions de dollars en liquidités et investissements, des dépenses en R&D de 19,8 millions de dollars, et une perte nette de 22,8 millions de dollars (0,32 dollar par action) pour le troisième trimestre 2024.
Altimmune (ALT) gab im dritten Quartal 2024 wichtige Entwicklungen bekannt, darunter den Abschluss der Rekrutierung in der Phase 2b IMPACT-Studie zu pemvidutide bei MASH, wobei die ersten Daten im zweiten Quartal 2025 erwartet werden. Das Unternehmen hat erfolgreich sein End-of-Phase-2-Meeting mit der FDA für das Adipositas-Programm von pemvidutide abgeschlossen und plant vier Phase-3-Studien. Auf der EASD wurden vielversprechende Daten präsentiert, die die Erhaltung der mageren Muskelmasse und die Reduktion des viszeralen Fettes durch pemvidutide zeigen. Das Unternehmen plant, ab dem vierten Quartal 2024 INDs für bis zu drei weitere Indikationen von pemvidutide einzureichen.
Die finanziellen Ergebnisse zeigten 139,4 Millionen US-Dollar an Bargeld und Investitionen, Forschungs- und Entwicklungskosten von 19,8 Millionen US-Dollar sowie einen Nettoverlust von 22,8 Millionen US-Dollar (0,32 US-Dollar pro Aktie) für das dritte Quartal 2024.
- Completed enrollment in Phase 2b IMPACT trial for MASH indication
- Successfully completed End-of-Phase 2 FDA meeting for obesity program
- Strong cash position of $139.4 million
- Promising clinical data showing 21.9% lean loss ratio and 28.3% visceral adipose tissue reduction
- Net loss increased to $22.8 million from $20.7 million year-over-year
- R&D expenses increased to $19.8 million from $18.4 million year-over-year
- G&A expenses rose to $5.0 million from $4.5 million year-over-year
Insights
The Q3 results and business update reveal several significant developments for Altimmune. With
The quarterly net loss of
The clinical development strategy for pemvidutide shows promising differentiation in the competitive obesity and MASH markets. Key highlights include the impressive lean mass preservation with a
The planned expansion into multiple new indications, supported by four Phase 3 obesity trials, demonstrates pemvidutide's potential broad therapeutic utility. The dual GLP-1/glucagon mechanism offers a unique approach that could address multiple metabolic pathways, potentially differentiating it from current GLP-1 focused therapies.
Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025
Successful completion of the obesity End-of-Phase 2 meeting with the FDA
Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning Q4 2024
Cash, cash equivalents and short-term investments of
Webcast to be held today, November 12, 2024, at 8:30 a.m. ET
GAITHERSBURG, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.
“In the third quarter, we reached several important milestones, most notably the completion of enrollment in the Phase 2b IMPACT trial of pemvidutide in MASH, positioning us to report top-line efficacy data in the second quarter of 2025,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “Further, we successfully completed our End-of-Phase 2 meeting with the FDA for the pemvidutide Phase 3 obesity program, gaining agreement on the design of the pivotal studies as well as the measures of efficacy and safety.”
Dr. Garg continued, “The Phase 3 program is designed to leverage the key attributes of pemvidutide, including the effects of balanced GLP-1/glucagon dual agonism in subjects with overweight and obesity. The program will include four pivotal trials with a primary efficacy endpoint of weight loss and will evaluate the effects of pemvidutide on principal co-morbidities of obesity, including elevated serum lipids and excess liver fat. The program will also assess the preservation of lean mass and its impact on subjects at risk for loss of physical function and other complications of sarcopenia.”
“At the 60th Annual Meeting of the European Association for the Study of Diabetes, we presented compelling data from our Phase 2 MOMENTUM trial of pemvidutide in obesity, which highlighted its class-leading preservation of lean mass and preferential reduction in visceral adipose tissue, both of which are important differentiators for pemvidutide,” said Scott Harris, M.D., Chief Medical Officer of Altimmune. “We also remain on-track to submit an IND application this quarter for the first of up to three additional indications for pemvidutide, with the trial expected to initiate in the first half of 2025.”
Dr. Garg concluded, “The data we have generated to date, coupled with the multiple key inflection points on the horizon, give us confidence that 2025 will be a transformational year for pemvidutide, and for Altimmune.”
Recent Highlights and Anticipated Milestones:
Metabolic Dysfunction-Associated Steatohepatitis (MASH):
- The Company completed patient enrollment in IMPACT, a biopsy-driven Phase 2b trial of pemvidutide in MASH
- The IMPACT trial is evaluating the efficacy and safety of pemvidutide in approximately 190 subjects with biopsy-confirmed MASH.
- With a successful readout from IMPACT, pemvidutide would be the first MASH therapy to achieve both fibrosis improvement and significant weight loss at 24 weeks of treatment.
- Top-line efficacy data is expected in Q2 2025.
Obesity:
- Completed End-of-Phase 2 Meeting for the obesity program with the FDA
- Agreement was reached on the plan for four Phase 3 clinical trials that leverage the key attributes of pemvidutide including balanced GLP-1/glucagon dual agonism.
- Each of the four studies is designed to assess the ability of pemvidutide treatment to drive meaningful weight loss and address co-morbidities in specific subpopulations of patients with overweight or obesity.
- Data from these studies are expected to form the basis for a registrational package to support FDA approval of pemvidutide in obesity.
- The Company presented data from a body composition sub-study from the Phase 2 MOMENTUM trial at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD)
- In an MRI evaluation of subjects with overweight and obesity treated with pemvidutide for 48 weeks, the lean loss ratio was
21.9% . - Lean mass preservation was greater in subjects aged 60 years and older, in whom the lean loss ratio was further reduced to
19.9% . - In addition to the preservation of lean mass, visceral adipose tissue (VAT) was reduced by
28.3% in the 2.4mg cohort at Week 48. Reduction of VAT is important as VAT is closely associated with cardiovascular risk.
- In an MRI evaluation of subjects with overweight and obesity treated with pemvidutide for 48 weeks, the lean loss ratio was
Additional Indications for Pemvidutide:
- The Company plans to submit IND applications for pemvidutide in up to three additional indications
- The first of these IND applications will be submitted in Q4 2024, with remaining IND applications expected to be submitted in the first half of 2025.
- Preparations for the first trial are underway, with initiation planned for H1 2025.
Corporate Update:
- On November 11, 2024, the Company announced the appointment of life sciences industry veteran Greg Weaver as Chief Financial Officer
Financial Results for the Three Months Ended September 30, 2024:
- Altimmune had cash, cash equivalents and short-term investments totaling
$139.4 million on September 30, 2024. - Research and development expenses were
$19.8 million for the three months ended September 30, 2024, compared to$18.4 million in the same period in 2023. The expenses for the quarter ended September 30, 2024, included$12.4 million in direct costs related to development activities for pemvidutide and$0.8 million in direct costs related to additional research and discovery projects. - General and administrative expenses were
$5.0 million for the three months ended September 30, 2024, compared to$4.5 million in the same period in 2023. The increase was primarily due to a$0.4 million increase in professional fees. - Interest income was consistent period-over-period at
$1.9 million for each of the three months ended September 30, 2024 and 2023. - Net loss for the three months ended September 30, 2024, was
$22.8 million , or$0.32 net loss per share, compared to a net loss of$20.7 million , or$0.39 net loss per share, in the same period in 2023.
Conference Call Information:
| Date: | November 12, 2024 |
| Time: | 8:30 a.m. Eastern Time |
| Webcast: | To listen, the conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors. |
| Dial-in: | To participate or dial-in, register here to receive the dial-in numbers and unique PIN to access the call. |
Following the conclusion of the call, the webcast will be available for replay on the Investor Relations (IR) page of the Company’s website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss with class-leading lean mass preservation, and robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Forward-Looking Statement
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of the IMPACT trial data readout, the timing of the planned End-of-Phase 2 FDA meeting, the timing of the planned IND submissions for pemvidutide, the timing of key milestones for any of our clinical assets, and the prospects for the utility of, regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; the Company’s ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K and our other filings with the SEC, which are available at www.sec.gov.
Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
| ALTIMMUNE, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per-share amounts) | ||||||||
| September 30, | December 31, | |||||||
| 2024 | 2023 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 31,474 | $ | 135,117 | ||||
| Restricted cash | 42 | 41 | ||||||
| Total cash, cash equivalents and restricted cash | 31,516 | 135,158 | ||||||
| Short-term investments | 107,906 | 62,698 | ||||||
| Accounts and other receivables | 428 | 1,111 | ||||||
| Income tax and R&D incentive receivables | 2,912 | 3,742 | ||||||
| Prepaid expenses and other current assets | 2,997 | 6,917 | ||||||
| Total current assets | 145,759 | 209,626 | ||||||
| Property and equipment, net | 446 | 651 | ||||||
| Other assets | 1,659 | 363 | ||||||
| Total assets | $ | 147,864 | $ | 210,640 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,133 | $ | 2,070 | ||||
| Accrued expenses and other current liabilities | 7,505 | 10,073 | ||||||
| Total current liabilities | 8,638 | 12,143 | ||||||
| Other noncurrent liabilities | 5,849 | 4,398 | ||||||
| Total liabilities | 14,487 | 16,541 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock, | 7 | 7 | ||||||
| Additional paid-in capital | 676,425 | 665,427 | ||||||
| Accumulated deficit | (538,210 | ) | (466,331 | ) | ||||
| Accumulated other comprehensive loss, net | (4,845 | ) | (5,004 | ) | ||||
| Total stockholders’ equity | 133,377 | 194,099 | ||||||
| Total liabilities and stockholders’ equity | $ | 147,864 | $ | 210,640 | ||||
| ALTIMMUNE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per-share amounts) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenues | $ | 5 | $ | 362 | $ | 15 | $ | 389 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 19,803 | 18,388 | 62,445 | 48,890 | ||||||||||||
| General and administrative | 4,969 | 4,514 | 15,876 | 13,805 | ||||||||||||
| Total operating expenses | 24,772 | 22,902 | 78,321 | 62,695 | ||||||||||||
| Loss from operations | (24,767 | ) | (22,540 | ) | (78,306 | ) | (62,306 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | (6 | ) | (29 | ) | (8 | ) | (33 | ) | ||||||||
| Interest income | 1,910 | 1,884 | 6,505 | 5,387 | ||||||||||||
| Other income (expense), net | 18 | 14 | (70 | ) | 146 | |||||||||||
| Total other income (expense), net | 1,922 | 1,869 | 6,427 | 5,500 | ||||||||||||
| Net loss | (22,845 | ) | (20,671 | ) | (71,879 | ) | (56,806 | ) | ||||||||
| Other comprehensive income — unrealized gain on short-term investments | 347 | 56 | 159 | 103 | ||||||||||||
| Comprehensive loss | $ | (22,498 | ) | $ | (20,615 | ) | $ | (71,720 | ) | $ | (56,703 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.32 | ) | $ | (0.39 | ) | $ | (1.01 | ) | $ | (1.10 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 71,084,787 | 53,633,354 | 70,927,222 | 51,495,957 | ||||||||||||
This press release was published by a CLEAR® Verified individual.
FAQ
When will Altimmune (ALT) report top-line data from the Phase 2b IMPACT trial?
How many Phase 3 trials is Altimmune (ALT) planning for pemvidutide in obesity?
What was Altimmune's (ALT) cash position as of September 30, 2024?
What were the key clinical results presented by Altimmune (ALT) at EASD 2024?
